SLXN · Silexion Therapeutics Corp · Analyst Estimates
$1.37
-0.14 (-9.00%)
At close · Nov 20
Return incl. dividend (before tax)
Going-concern doubt
— flagged Nov 12, 2026
Substantial doubt about the company's ability to continue as a going concern.
“As of September 30, 2026, we had cash and cash equivalents of $4.8 million. Based on our current cash balance, as well as our history of operating losses and negative cash flows from operations, combined with our anticipated use of cash to, among other things, (i) fund the clinical development of SIL204, (ii) identify and develop new product candidates, and (iii) seek approval for SIL204 and any other product candidates we may develop, our management has concluded that we do not have sufficient cash to fund our operations for 12 months from the issuance date of our consolidated financial statements for the three-month and nine-month periods ended September 30, 2026 included in this quarterly report, but rather, for only several months from the filing date of this quarterly report, under our current business plan, as a result, there is substantial doubt about our ability to continue as a going concern.”View the 10-Q filed Nov 12, 2026
Market Cap
$974,292
Shares
649,528
Volume · Nov 20
8338
Avg daily vol (7 sessions)
84.05K
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Analyst Estimates
Compare analyst forecasts for Silexion Therapeutics Corp across metrics and forecast periods.
Estimates are grouped by forecast period, with low, average and high together. A dash means that statistic is not available.
Pull consensus estimates through the analyst estimates API or MCP →Compiled consensus
These figures are a compiled consensus of analyst forecasts, not a survey the company published itself. Every figure is the statistic the source states; averages are means, never medians.
Captured 2026-11-14 14:11 UTC · Publication dates shown per estimate · 5 metric / period groups
FY ending 2026-12-31
| Metric | Low | Average | High | Analyst count | Average, 7 days ago | Average, 30 days ago | Average, 60 days ago | Average, 90 days ago | Estimates lowered, last 7 days | Estimates lowered, last 30 days | Estimates raised, last 7 days | Estimates raised, last 30 days |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
EPS
USD
Publication date not stated |
-112.80
|
-112.80
|
-112.80
|
1
|
-116.28
|
-116.28
|
-119.76
|
-127.44
|
0
|
0
|
0
|
0
|
|
Revenue
USD
Publication date not stated |
0.00
|
0.00
|
0.00
|
1
|
— | — | — | — | — | — | — | — |
FY ending 2027-12-31
| Metric | Low | Average | High | Analyst count | Average, 7 days ago | Average, 30 days ago | Average, 60 days ago | Average, 90 days ago | Estimates lowered, last 7 days | Estimates lowered, last 30 days | Estimates raised, last 7 days | Estimates raised, last 30 days |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
EPS
USD
Publication date not stated |
-44.16
|
-44.16
|
-44.16
|
1
|
-48.60
|
-48.60
|
-446.52
|
-444.36
|
0
|
0
|
1
|
1
|
|
Revenue
USD
Publication date not stated |
0.00
|
0.00
|
0.00
|
1
|
— | — | — | — | — | — | — | — |
Q ending 2026-09-30
| Metric | Low | Average | High | Analyst count | Average, 7 days ago | Average, 30 days ago | Average, 60 days ago | Average, 90 days ago | Estimates lowered, last 7 days | Estimates lowered, last 30 days | Estimates raised, last 7 days | Estimates raised, last 30 days |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Revenue
analysts
Publication date not stated |
— | — | — |
0
|
— | — | — | — | — | — | — | — |
Key facts
CIK
2022416
CUSIP
G1281K148
13F (30d)
13 filings
11 filers
Visit website
Investor relations